通过免疫微环境参数预测胃肠胰神经内分泌肿瘤的177Lu-DOTATATE治疗反应
该研究对50例神经内分泌肿瘤患者肿瘤切片行多重免疫荧光染色以描述免疫微环境,并在20例接受177Lu-DOTATATE治疗的患者中分析基线免疫微环境与疗效及无进展生存期的关系,发现反应良好者基线调节性T细胞及CD8+TIM-3+细胞密度较低、调节性T细胞与CD8+T细胞等间距较大。
要点
- 177Lu-DOTATATE治疗的总体缓解率为60%。
- 反应良好者基线调节性T细胞与CD8+TIM-3+细胞密度较低,调节性T细胞与CD8+T细胞、CD11c+树突状细胞及CD163+M2巨噬细胞间距较大。
- 基于逻辑回归的疗效预测模型经内部验证保持良好区分度,Counts-(CD163)(CD11c)与治疗后无进展生存期正相关。
核心结论
- 胃肠胰神经内分泌肿瘤患者的免疫微环境参数与177Lu-DOTATATE治疗疗效密切相关,研究结果为预测疗效和患者选择提供了潜在工具。
研究设计与样本
- 研究采用多重免疫荧光染色对50例神经内分泌肿瘤患者的肿瘤切片进行免疫微环境细胞密度与空间组织特征分析。
- 在20例接受177Lu-DOTATATE治疗的患者中,探讨基线免疫微环境与治疗疗效及预后的关系。
主要发现
- 胃肠胰神经内分泌肿瘤患者呈现免疫抑制性微环境。
- 177Lu-DOTATATE治疗的总体缓解率为60%。
- 反应良好(部分缓解或完全缓解)的患者基线调节性T细胞与CD8+TIM-3+细胞密度较低,调节性T细胞与CD8+T细胞、调节性T细胞与CD11c+树突状细胞、调节性T细胞与CD163+M2巨噬细胞之间的最近邻距离较大。
- 反应不佳(疾病稳定或疾病进展)的患者CD8+T细胞与树突状细胞之间距离较大,CK+肿瘤细胞与CD8+TIM-3+细胞之间呈更多聚集模式。
- 基于逻辑回归建立的177Lu-DOTATATE疗效预测模型经内部验证后保持良好区分度;Counts-(CD163)(CD11c)与177Lu-DOTATATE治疗后无进展生存期正相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following metastasis is often poor. The efficacy of 177Lu-DOTATATE therapy and the subgroups that benefit from it remain unclear. Our objective is to characterize the composition of the tumor immune microenvironment in GEP-NETs and to identify predictive biomarkers associated with response and PFS following 177Lu-DOTATATE. METHODS: Multiplex immunofluorescence (mIF) staining of tumor sections was used to characterize the cellular density and spatial organization of the microenvironment of 50 NET patients. The relationship between baseline immune microenvironment and 177Lu-DOTATATE efficacy or prognosis in 20 177Lu-DOTATATE-treated patients was explored. RESULTS: Patients with GEP-NET exhibited an immunosuppressive microenvironment. The overall response rate (ORR) to 177Lu-DOTATATE therapy was 60%. Patients with a good response (partial response or complete response) had a lower density of regulatory T cells (Tregs) and CD8+TIM-3+ cells at baseline, with greater nearest neighbor distances between Tregs and CD8+ T cells, Tregs and CD11c+ dendritic cells (DCs), as well as Tregs and CD163+ M2 macrophages. Conversely, patients with a poor response (stable disease or progressive disease) had greater distances between CD8+ T cells and DCs, and more clustering pattern between CK+ tumor cells and CD8+TIM-3+ cells. Furthermore, a logistic regression-based predictive model for 177Lu-DOTATATE efficacy was established, which maintained good discrimination after internal validation. Finally, the study revealed that Counts-(CD163)(CD11c) positively correlated with progression-free survival (PFS) post-177Lu-DOTATATE. CONCLUSIONS: The immune microenvironment parameters of GEP-NET patients are closely associated with 177Lu-DOTATATE therapy efficacy. Our findings provide a potential tool for predicting 177Lu-DOTATATE efficacy and patient selection, offering direction for precision clinical strategies and potential combination therapies in GEP-NET.
引用
- Zeng Z, Zhang Z, Xie Q, et al. Predicting 177Lu-DOTATATE therapy response through immune microenvironment parameters in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Eur J Nucl Med Mol Imaging. 2025. PMID: 40762799. doi:10.1007/s00259-025-07458-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。